New hope for controlling rare genetic tumors
Disease control
Ongoing
This study is testing two repurposed cancer drugs, brigatinib and neratinib, to see if they can slow or stop the growth of tumors in people with NF2-related schwannomatosis. It will enroll about 100 participants aged 12 and older who have specific, growing tumors. The trial uses …
Phase: PHASE2 • Sponsor: Scott R. Plotkin, MD, PhD • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC